The MR-OPERA multi-center study is now published in the Red Journal

The MRI Only Prostate External Radiotherapy (MR-OPERA) study is now published in the prestigious International Journal of Radiation Oncology (a.k.a. the Red Journal). The MR-OPERA study comprises a joint effort by four Swedish university hospitals, involving 170 patients, aiming at validating the use of Spectronic Medical's MriPlanner technology for prostate cancer radiotherapy.

"The MR-OPERA study is the world's largest study evaluating an MRI only workflow for radiotherapy planning. The fantastic efforts made by the participating hospitals to make this study possible shows how important our technology is to the future of radiotherapy", says Carl Siversson, CEO of Spectronic Medical.

The uniform conclusion of the study is that MRI only radiotherapy planning using MriPlanner is both accurate and robust, and also works well with a large variety of MRI scanners and clinical environments.

"The extraordinary results shows not only that our technology works very well, but also that it is now ready for large-scale deployment", says Carl Siversson and continues, "The advantages of an MRI only workflow are enormous. Not only are costs reduced and patient comfort increased, but it also opens up for personalized treatment strategies with significant therapeutic benefits"

MriPlanner is currently CE marked and ready for prostate radiotherapy planning in Europe and other regions acknowledging the CE mark. FDA approval for the US market will follow soon.

The complete MR-OPERA study can be read here:

Major milestone: First set of prostate cancer patients treated using Spectronic Medical's MriPlanner technology

A major milestone is now reached in Spectronic Medical's development history. During the past weeks, the first set of prostate cancer patients were successfully treated at Skåne University Hospital using Spectronic Medical's MriPlanner technology. In total 60 patients are included for therapy at Skåne University Hospital using MriPlanner during 2016.

"This is not only a milestone for us but also for the national medical achievements in this field, as these treatments are the first of their kind ever to be performed in Sweden. Our MRI only radiotherapy planning technology not only reduces treatment complexity but also opens up for very exciting personalized and adaptive treatment planning strategies." says Carl Siversson, CEO of Spectronic Medical.

The MR-OPERA study is presented at the ESTRO conference in Vienna

The MR Only Prostate External Radiotherapy (MR-OPERA) multi center validation study is presented at the ESTRO scientific conference in Vienna May 5-9. The national MR-OPERA study was performed as a collaboration between Skåne University Hospital, Norrland University hospital, Sahlgrenska University Hospital and Karolinska University hospital aiming to verify and validate Spectronic Medical's MriPlanner technology with a large cohort of 170 prostate cancer patients.

"The results presented at ESTRO are very exciting and confidently shows that our technology is robust and ready for large-scale clinical implementation", says Carl Siversson, CEO of Spectronic Medical.

The study will be presented by first author Emilia Persson from Lund University on Saturday May 6. Spectronic CEO Carl Siversson will also attend ESTRO. Please contact us if you wish to arrange a meeting at ESTRO.

Spectronic Medical is awarded as one of Sweden's 33 hottest young technology companies

At an event hosted by NyTeknik and Affärsvärlden at Münchenbryggeriet in Stockholm, Spectronic Medical was awarded as one of Sweden's 33 hottest young technology companies.

"We are very happy for this recognition", says Carl Siversson, CEO of Spectronic Medical, "This award verifies our understanding that the market is now asking for the type of advanced AI driven med-tech technology we are providing".

Apart from receiving the award, Spectronic Medical also participated the event with a booth displaying its technology to a wider audience.

The awards were further recognized by Nasdaq at Times Square in New York.


Read more here:

Winner of the 33 list competition in southern Sweden

In tough competition Spectronic Medical came out on top in the 33-list* pitching competition held in Malmö on the 8th of March. Thereby Spectronic Medical has now earned a place one 33-list; enlisting the 33 hottest young technology companies in Sweden.

The Jury Motivation:
"Spectronic Medical uses powerful, self-learning algorithms with ingenious elimination of CT radiation to create a cancer treatment that is more precise, gentle, and without human error."

Read more on the links below (in Swedish):

Ny Teknik:

Winning interview with Spectronic Medical's CEO Carl Siversson:


*The 33-list, listing "Sweden's 33 hottest young technology companies", is compiled jointly by the editorial staff of the magazines Ny Teknik and Affärsvärlden. The complete list of all companies will be presented in Stockholm on the 4th of April at Münchenbryggeriet.


Spectronic Medical is selected to join the 33-list pitching competition

Spectronic Medical is selected to join the 33-list pitching competition for a place on the 33-list. The 33-list, listing "Sweden's 33 hottest young technology companies", is compiled jointly by the editorial staff of the magazines Ny Teknik and Affärsvärlden. “It is very exciting to be selected to present our technology to a wider audience” said Dr. Carl Siversson, CEO of Spectronic Medical. “While there only is a very short time for presenting a complex technology we will gladly take on the challenge to spread awareness of the positive development going on within the cancer care area”.

Wish us good luck and join us, for free, at Media Evolution in Malmö on the 8th March. Sign up at:

Spectronic Medical joins part three of the gentle radiotherapy project

The gentle radiotherapy research project aims to create a large-scale national cancer therapy platform, with fully integrated MRI only workflow in the participating clinics. The individual clinics are responsible for developing treatment procedures for a specific cancer diagnosis; e.g. prostate, rectum, head-neck and brain. Hence, the project as a whole aims to cover the major parts of the body where MR images are relevant for therapy. The role of Spectronic Medical in the project is to supply the technology for creation of synthetic CT’s (sCT) as well as technology for QA of geometric distortion.

The steps taken by Gentle Radiotherapy project to advance MRI only treatment planning are very well aligned with our development efforts” says Dr. Carl Siversson, CEO of Spectronic Medical. “We are of course supporting the transition to MRI only based treatments and will strengthen our development efforts to be able to supply technology for more anatomical regions”.

Today Spectronic Medical have a CE Marked product for generation of sCT’s for prostate cancer radiotherapy.

Spectronic Medical receives CE Mark for MriPlanner

Spectronic Medical announced today that it has received CE Mark approval for the commercial sale of its MriPlanner product. MriPlanner is the innovative product enabling MRI only based radiation therapy treatment planning for prostate cancer.

This is a major milestone in radiation therapy. MriPlanner eliminates the troublesome usage of dual imaging modalities, reducing both complexity and cost while bringing increased treatment performance” said Dr. Carl Siversson, CEO of Spectronic Medical.

Today both Magnetic Resonance (MR) and Computed Tomography (CT) images are used in radiation therapy. An MR image is superior to a CT when it comes to contrast of soft tissue, enabling medical staff to improve treatment of the disease. However, the CT image has so far still been needed since the MR image lacks the electron density information required for radiation dose calculations. Unfortunately, usage of dual imaging modalities does not come without drawbacks. Matching the two images, taken in different scanners at different times, will always introduce uncertainties. Secondly, using two scanners is more expensive both with regard to equipment and manual labor. Finally, the dual scanner workflow requires careful scheduling of patients and also adds additional discomfort for the patients, who are already in a very exposed situation.

MriPlanner now addresses these problems by generating a synthetic CT (sCT) from a single MR image. In addition, suggested delineations of organs at risk (OAR) are also provided; greatly reducing the time required for clinical personnel to create the final treatment plan.

Besides the obvious benefits of basing the radiotherapy treatment plan on a MR image this also paves the way for adaptive treatments, which has not been possible with the conventional CT based workflow” commented Carl Siversson.

MR in RT 2016 participation and preliminary results from MR-OPERA study

Spectronic Medical will participate at the MRinRT symposium held in Ann Arbor, Michigan (US) on the 18th – 19th June 2016.

In May, full enrollment of the 170-patient MR-OPERA Study was completed and some very promising initial results will be announced at the MRinRT symposium. The MR-OPERA Study aims to validate the MriPlanner software for MR to CT conversion for the use in a MR only prostate external radiotherapy workflow. Using a multi-center study setup, at the four principal university hospitals of Sweden, CT-based treatment plans are compared to synthetic CT plans for 170 prostate cancer patients.

Spectronic Medical presents the Statistical decomposition algorithm

In a new scientific paper [Siversson et al, Med. Phys. 42, 6090 (2015)] Dr. Carl Siversson, CEO of Spectronic Medical, presents the patented Statistical decomposition algorithm (SDA). The SDA provides a method for automatic generation of synthetic CT (sCT) images from a single MR image volume. The algorithm is based on automatic tissue classification in combination with a model trained using a multimodal template material.

The presented study compares dose calculations between sCT generated by the SDA and conventional CT in the male pelvic region. The conclusion is that SDA enables a highly accurate MRI only workflow in prostate radiotherapy planning. The dosimetric uncertainties originating from the SDA appear negligible and are notably lower than the uncertainties introduced by variations in patient geometry between imaging sessions.